Ocular Therapeutix Inc (NASDAQ:OCUL) — Market Cap & Net Worth
Market Cap & Net Worth: Ocular Therapeutix Inc (OCUL)
Ocular Therapeutix Inc (NASDAQ:OCUL) has a market capitalization of $2.35 Billion ($2.35 Billion) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #5642 globally and #1851 in its home market, demonstrating a 0.75% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ocular Therapeutix Inc's stock price $10.72 by its total outstanding shares 219615868 (219.62 Million). Also see Ocular Therapeutix Inc (OCUL) total assets for a full breakdown of the balance sheet.
Ocular Therapeutix Inc Market Cap History: 2015 to 2026
Ocular Therapeutix Inc's market capitalization history from 2015 to 2026. Data shows change from $2.06 Billion to $2.35 Billion (-4.08% CAGR). Also see OCUL cash flow metrics for how efficiently the company converts equity into cash flow.
Index Memberships
Ocular Therapeutix Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.68 Trillion | 0.09% | #156 of 976 |
|
NASDAQ Composite
IXIC
|
$41.94 Trillion | 0.01% | #649 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.89 Trillion | 0.12% | #97 of 263 |
Weight: Ocular Therapeutix Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ocular Therapeutix Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ocular Therapeutix Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Ocular Therapeutix Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
51.45x
Ocular Therapeutix Inc's market cap is 51.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.84 Billion | $1.89 Million | -$44.70 Million | 974.13x | N/A |
| 2017 | $977.29 Million | $1.92 Million | -$63.39 Million | 508.21x | N/A |
| 2018 | $874.07 Million | $1.99 Million | -$57.69 Million | 439.23x | N/A |
| 2019 | $867.48 Million | $4.23 Million | -$86.37 Million | 205.22x | N/A |
| 2020 | $4.55 Billion | $17.40 Million | -$155.64 Million | 261.22x | N/A |
| 2021 | $1.53 Billion | $43.52 Million | -$6.55 Million | 35.17x | N/A |
| 2022 | $617.12 Million | $51.49 Million | -$71.04 Million | 11.98x | N/A |
| 2023 | $979.49 Million | $58.44 Million | -$80.74 Million | 16.76x | N/A |
| 2024 | $1.88 Billion | $63.72 Million | -$193.51 Million | 29.43x | N/A |
| 2025 | $2.67 Billion | $51.82 Million | -$265.94 Million | 51.45x | N/A |
Competitor Companies of OCUL by Market Capitalization
Companies near Ocular Therapeutix Inc in the global market cap rankings as of September 15, 2026. Review OCUL tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ocular Therapeutix Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #338 globally with a market cap of $80.28 Billion USD.
- CSL Ltd (AU:CSL): Ranked #463 globally with a market cap of $58.90 Billion USD ( AU$83.24 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #509 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $519.51 |
| #338 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.28 Billion | $793.74 |
| #463 | CSL Ltd | AU:CSL | $58.90 Billion | AU$171.57 |
| #509 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $146.69 |
Ocular Therapeutix Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Ocular Therapeutix Inc's market cap moved from $2.06 Billion to $ 2.35 Billion, with a yearly change of -4.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.35 Billion | -11.70% |
| 2025 | $2.67 Billion | +42.15% |
| 2024 | $1.88 Billion | +91.48% |
| 2023 | $979.49 Million | +58.72% |
| 2022 | $617.12 Million | -59.68% |
| 2021 | $1.53 Billion | -66.33% |
| 2020 | $4.55 Billion | +424.05% |
| 2019 | $867.48 Million | -0.75% |
| 2018 | $874.07 Million | -10.56% |
| 2017 | $977.29 Million | -46.83% |
| 2016 | $1.84 Billion | -10.67% |
| 2015 | $2.06 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 15th, 2026 the market cap of Ocular Therapeutix Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.35 Billion USD |
| MoneyControl | $2.35 Billion USD |
| MarketWatch | $2.35 Billion USD |
| marketcap.company | $2.35 Billion USD |
| Reuters | $2.35 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ocular Therapeutix Inc
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as wel… Read more